The disposable biopsy needle is used for guided elimination of tissue samples in frameless neurosurgical processes. It is a method to get a sample of cells for laboratory testing from the patient’s body. Generally, the needle biopsy process involves core needle biopsy and fine-needle aspiration. These needles are generally made of durable materials like stainless steel or other materials with a hollow, sharp tip. This needle is widely used in hospital, ambulatory center, and in other to diagnose and manage various disorder.
Augmenting the prevalence of cancer cases globally is considered as one of the foremost factors influencing the growth of market. Several factors are attributed to the growing cancer rate such as tobacco use, change in lifestyle, alcohol consumption, obesity, unhealthy diet, and many other aspects. Revelation to environmental toxins like pesticides, air pollution, and radiation are also responsible to growing risks of cancer. For instance, according to World Health Organization, in 2020, there were nearly 10 million deaths from cancer. The diagnosis of disease and monitoring the effectiveness of cancer treatments has become vital. This has further enhanced the sales of disposable biopsy needles. Moreover, escalating demand for minimally invasive operations, as well as government and health organization support from various countries globally, is likely to spur the market. Apart from this, product innovation and launches by many industry participants are flourishing on the global market. Many businesses across the global are improving their businesses by executing various strategies. For example, in 2021, Cook Medical introduced the EchoTip ProCore HD Ultrasound Biopsy Needle, which offers high-definition ultrasound imaging and a larger biopsy sample size. Likewise, many other leading players, such as Becton, Dickinson and Company, Olympus Corporation, and many others, have contributed to the market. This has dramatically helped the disposable biopsy needle market grow at a rapid pace.
Despite several growth factors, the availability of many alternative products for disease diagnosis is hampering the growth of the market. For example, fine-needle aspiration is a minimally invasive technique that involves using a thin needle to extract cells from a mass or lesion for examination. fine needle aspiration (FNA) is often used to diagnose breast lumps, thyroid nodules, and some types of cancer. In addition, lack of resources in developing countries and an immature healthcare infrastructure are impeding the market. Furthermore, several R&D efforts as well as the rising adoption of emerging technologies such as vacuum-assisted biopsy, radiofrequency biopsy needles, and many other technologies will create a plethora of opportunities in the global market.
New product launches to flourish in the market
In August 2020, The Brevera Breast Biopsy System with CorLumina Imaging Technology, the global first and only breast biopsy solution to combine vacuum-assisted tissue acquisition, real-time imaging verification, and sophisticated post-biopsy handling in one integrated system, has undergone improvements, according to Hologic, Inc., an innovative medical technology company primarily focused on improving women's health. The Brevera system includes a reusable device driver and disposable needles to simplify storage and enhance waste management to better fulfill clinician needs. Furthermore, Olympus, a leader in the field of technology and a provider of cutting-edge products for both medical and surgical procedures, has received FDA approval for its EZ Shot 3 Plus 25 G needle and an expanded indication for the product line's use in both FNA and fine needle biopsy. As technology continues to advance and demand for minimally invasive diagnostic and treatment options grows, innovation in this field will enhance day by day.
The disposable biopsy needle market is segmented on the basis of application, end user, and region. By application, it is divided into cancer/tumor, infectious diseases, autoimmune disorder, and others. By end user, it is divided into hospitals, ambulatory surgical center, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Overview:
By application: The disposable biopsy needle market is categorized into cancer/tumor, infectious diseases, autoimmune disorders, and others. To diagnosis and treat numerous diseases like cancer, autoimmune disorder, and other noninfectious conditions, biopsy needles play an important role. For identifying the precise or accurate kind of microbe which causes abscesses or deep-seated infections, biopsy is dramatically required. These needles may also be used in the observation and treatment of autoimmune diseases. For patients with lupus, a chronic autoimmune illness that can affect numerous organ systems, a skin biopsy may be used to track disease activity.
By end use: The disposable biopsy needle market is segmented into hospitals, ambulatory surgical centres, and others. Ambulatory care centers provide same-day medical services, which involve diagnostic tests, outpatient surgical procedures, and other medical treatments that do not need hospital admission. With help of disposable biopsy needles, many ambulatory centers can be performed on an outpatient basis and are minimally invasive. These needles are gaining huge traction in hospitals. Moreover, hospitals can certify precise diagnosis, provide cost-effective care for patients, and also help to reduce the risks of infection and complications.
By region: North America is leading the global market with major market share. Growing cancer patients in the region due to huge tobacco consumption, evolving technologies in the healthcare sector, and heightening healthcare expenditure are contributing to the growth of market in this region. Comparatively, the U.S. spent highest money on the healthcare than other countries as the country is known for its remarkable, cutting-edge medical technologies. The expense of healthcare increases because these technical developments are frequently more expensive than more traditional, well-established treatments. For example, in 2021, health spending was augmented by 2.7% in the U.S., to approximately US$ 4.3 trillion. The people require more healthcare facilities as they get older, involving chronic disease management and long-term care. All these factors are helping the disposable biopsy needles market grow with a significant share in the North American region. It is expected that the region will maintain its supremacy in the forthcoming years.
Competitive analysis and profiles of the major players in the disposable biopsy needle, such as Argon Medical Devices, Inc., B. Braun Melsungen AG, Becton, Boston Scientific Co., Cardinal Health, Cook Group Incorporated, Dickinson and Company, FUJIFILM Holdings Co., Hologic Inc., Medtronic plc, and Olympus Co. are provided in this report.
Augmenting the prevalence of cancer cases globally is considered as one of the foremost factors influencing the growth of market. Several factors are attributed to the growing cancer rate such as tobacco use, change in lifestyle, alcohol consumption, obesity, unhealthy diet, and many other aspects. Revelation to environmental toxins like pesticides, air pollution, and radiation are also responsible to growing risks of cancer. For instance, according to World Health Organization, in 2020, there were nearly 10 million deaths from cancer. The diagnosis of disease and monitoring the effectiveness of cancer treatments has become vital. This has further enhanced the sales of disposable biopsy needles. Moreover, escalating demand for minimally invasive operations, as well as government and health organization support from various countries globally, is likely to spur the market. Apart from this, product innovation and launches by many industry participants are flourishing on the global market. Many businesses across the global are improving their businesses by executing various strategies. For example, in 2021, Cook Medical introduced the EchoTip ProCore HD Ultrasound Biopsy Needle, which offers high-definition ultrasound imaging and a larger biopsy sample size. Likewise, many other leading players, such as Becton, Dickinson and Company, Olympus Corporation, and many others, have contributed to the market. This has dramatically helped the disposable biopsy needle market grow at a rapid pace.
Despite several growth factors, the availability of many alternative products for disease diagnosis is hampering the growth of the market. For example, fine-needle aspiration is a minimally invasive technique that involves using a thin needle to extract cells from a mass or lesion for examination. fine needle aspiration (FNA) is often used to diagnose breast lumps, thyroid nodules, and some types of cancer. In addition, lack of resources in developing countries and an immature healthcare infrastructure are impeding the market. Furthermore, several R&D efforts as well as the rising adoption of emerging technologies such as vacuum-assisted biopsy, radiofrequency biopsy needles, and many other technologies will create a plethora of opportunities in the global market.
New product launches to flourish in the market
In August 2020, The Brevera Breast Biopsy System with CorLumina Imaging Technology, the global first and only breast biopsy solution to combine vacuum-assisted tissue acquisition, real-time imaging verification, and sophisticated post-biopsy handling in one integrated system, has undergone improvements, according to Hologic, Inc., an innovative medical technology company primarily focused on improving women's health. The Brevera system includes a reusable device driver and disposable needles to simplify storage and enhance waste management to better fulfill clinician needs. Furthermore, Olympus, a leader in the field of technology and a provider of cutting-edge products for both medical and surgical procedures, has received FDA approval for its EZ Shot 3 Plus 25 G needle and an expanded indication for the product line's use in both FNA and fine needle biopsy. As technology continues to advance and demand for minimally invasive diagnostic and treatment options grows, innovation in this field will enhance day by day.
The disposable biopsy needle market is segmented on the basis of application, end user, and region. By application, it is divided into cancer/tumor, infectious diseases, autoimmune disorder, and others. By end user, it is divided into hospitals, ambulatory surgical center, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Overview:
By application: The disposable biopsy needle market is categorized into cancer/tumor, infectious diseases, autoimmune disorders, and others. To diagnosis and treat numerous diseases like cancer, autoimmune disorder, and other noninfectious conditions, biopsy needles play an important role. For identifying the precise or accurate kind of microbe which causes abscesses or deep-seated infections, biopsy is dramatically required. These needles may also be used in the observation and treatment of autoimmune diseases. For patients with lupus, a chronic autoimmune illness that can affect numerous organ systems, a skin biopsy may be used to track disease activity.
By end use: The disposable biopsy needle market is segmented into hospitals, ambulatory surgical centres, and others. Ambulatory care centers provide same-day medical services, which involve diagnostic tests, outpatient surgical procedures, and other medical treatments that do not need hospital admission. With help of disposable biopsy needles, many ambulatory centers can be performed on an outpatient basis and are minimally invasive. These needles are gaining huge traction in hospitals. Moreover, hospitals can certify precise diagnosis, provide cost-effective care for patients, and also help to reduce the risks of infection and complications.
By region: North America is leading the global market with major market share. Growing cancer patients in the region due to huge tobacco consumption, evolving technologies in the healthcare sector, and heightening healthcare expenditure are contributing to the growth of market in this region. Comparatively, the U.S. spent highest money on the healthcare than other countries as the country is known for its remarkable, cutting-edge medical technologies. The expense of healthcare increases because these technical developments are frequently more expensive than more traditional, well-established treatments. For example, in 2021, health spending was augmented by 2.7% in the U.S., to approximately US$ 4.3 trillion. The people require more healthcare facilities as they get older, involving chronic disease management and long-term care. All these factors are helping the disposable biopsy needles market grow with a significant share in the North American region. It is expected that the region will maintain its supremacy in the forthcoming years.
Competitive analysis and profiles of the major players in the disposable biopsy needle, such as Argon Medical Devices, Inc., B. Braun Melsungen AG, Becton, Boston Scientific Co., Cardinal Health, Cook Group Incorporated, Dickinson and Company, FUJIFILM Holdings Co., Hologic Inc., Medtronic plc, and Olympus Co. are provided in this report.
Disposable Biopsy Needle Market, by Application Report Highlights
| Aspects | Details |
 By Application |
|
 By End-use |
|
 By Region |
|
 Key Market Players | Argon Medical Devices, Inc., Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Medtronic plc, Olympus Corporation, FUJIFILM Holdings Corporation, Hologic Inc., Boston Scientific Corporation, Cook Group Incorporated, Cardinal Health |
Loading Table Of Content...
